Induction of varicella zoster virus DNA replication in dissociated human trigeminal ganglia.
Varicella zoster virus (VZV), a human neurotropic alphaherpesvirus, becomes latent after primary infection and reactivates to produce zoster. To study VZV latency and reactivation, human trigeminal ganglia removed within 24 h after death were mechanically dissociated, randomly distributed into six-well tissue culture plates and incubated with reagents to inactivate nerve growth factor (NGF) or phosphoinositide 3-kinase (PI3-kinase) pathways. At 5 days, VZV DNA increased in control and PI3-kinase inhibitor-treated cultures to the same extent, but was significantly more abundant in anti-NGF-treated cultures (p = 0.001). Overall, VZV DNA replication is regulated in part by an NGF pathway that is PI3-kinase-independent.
Department of Neurology, University of Colorado School of Medicine, 12700 E. 19th Avenue, Box B-182, Aurora, CO, 80045, USA. randall.cohrs@ucdenver.edu.|Department of Immunology and Microbiology, University of Colorado School of Medicine, 12700 E. 19th Avenue, Box B-182, Aurora, CO, 80045, USA. randall.cohrs@ucdenver.edu.
Randall J
RJ
Cohrs
Department of Neurology, University of Colorado School of Medicine, 12700 E. 19th Avenue, Box B-182, Aurora, CO, 80045, USA.
Hussain
H
Badani
Department of Neurology, University of Colorado School of Medicine, 12700 E. 19th Avenue, Box B-182, Aurora, CO, 80045, USA.
Nicholas L
NL
Baird
Department of Neurology, University of Colorado School of Medicine, 12700 E. 19th Avenue, Box B-182, Aurora, CO, 80045, USA.
Teresa M
TM
White
Department of Neurology, University of Colorado School of Medicine, 12700 E. 19th Avenue, Box B-182, Aurora, CO, 80045, USA.
Bridget
B
Sanford
Department of Neurology, University of Colorado School of Medicine, 12700 E. 19th Avenue, Box B-182, Aurora, CO, 80045, USA.|Department of Immunology and Microbiology, University of Colorado School of Medicine, 12700 E. 19th Avenue, Box B-182, Aurora, CO, 80045, USA.
Don
D
Gilden
D000328:Adult; D000368:Aged; D057134:Antibodies, Neutralizing / Q000494:pharmacology; D001344:Autopsy; D004261:DNA Replication; D004279:DNA, Viral / Q000096:biosynthesis / Q000235:genetics*; D005786:Gene Expression Regulation; D006562:Herpes Zoster / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000821:virology; D014645:Herpesvirus 3, Human / Q000235:genetics* / Q000378:metabolism / Q000472:pathogenicity; D054884:Host-Pathogen Interactions; D006801:Humans; D008297:Male; D008875:Middle Aged; D020932:Nerve Growth Factor / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics* / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D015398:Signal Transduction; D046509:Tissue Culture Techniques; D012668:Trigeminal Ganglion / Q000187:drug effects / Q000821:virology; D014775:Virus Activation; D017735:Virus Latency; D014779:Virus Replication
D057134:Antibodies, Neutralizing; D004279:DNA, Viral; D020932:Nerve Growth Factor; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors
Human; Latency; Nerve growth factor; Phosphoinositide-3-kinase; Trigeminal ganglion; VZV
Nat Rev Dis Primers. 2015 Jul 02;1:15016
27188665
J Virol. 2014 Jul;88(13):7379-88
24741093
J Infect Dis. 1988 Jul;158(1):117-23
2839575
Virus Genes. 2005 Oct;31(2):223-7
16025248
J Gen Virol. 2010 Dec;91(Pt 12):3002-9
20810749
J Virol. 2012 Sep;86(18):10203-6
22740396
PLoS Pathog. 2015 Jun 04;11(6):e1004885
26042814
J Virol. 2005 Nov;79(22):14079-87
16254342
J Virol. 1988 Feb;62(2):393-9
2826804
Lancet Neurol. 2007 Nov;6(11):1015-28
17945155
Neurol Res. 2000 Sep;22(6):565-6
11045016
J Virol. 2007 Mar;81(6):2950-6
17192313
Proc Natl Acad Sci U S A. 2013 Jul 9;110(28):E2621-8
23788661
J Virol. 2014 Jul;88(14):8189-92
24789785
Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4658-62
9539794
J Virol. 1986 Feb;57(2):446-55
3003377
Ann Neurol. 1987 Sep;22(3):377-80
2823688
J Virol. 1993 Apr;67(4):2381-4
8383249
Am J Otol. 1999 Jan;20(1):26-30
9918167
Cell. 2009 Jul 10;138(1):30-50
19596234
Infect Immun. 1978 Jan;19(1):199-203
203532
Virology. 1999 Jun 5;258(2):451-4
10366583
Ann Neurol. 2003 Nov;54(5):678-82
14595659
Cell Host Microbe. 2010 Oct 21;8(4):320-30
20951966
Trans Am Clin Climatol Assoc. 2012;123:17-33; discussion 33-5
23303966
J Neurovirol. 2016 Oct;22(5):688-694
27173396
J Neurovirol. 2012 Dec;18(6):456-61
22851387
J Virol. 2013 Feb;87(3):1842-8
23192871
Lancet. 1977 Sep 24;2(8039):637-9
71451
Proc Natl Acad Sci U S A. 2015 Sep 29;112(39):E5420-6
26305977
Can J Microbiol. 1982 Jan;28(1):123-9
6279261
Cell. 2007 Jun 29;129(7):1261-74
17604717
Ann Neurol. 1992 Apr;31(4):444-8
1316733
New Horiz Transl Med. 2015 Mar 1;2(3):89-91
26086038
Proc Natl Acad Sci U S A. 2016 Apr 26;113(17 ):E2403-12
27078099
Ann Neurol. 1977 Sep;2(3):249
215073
J Med Virol. 2000 Sep;62(1):42-5
10935987
J Neurovirol. 2011 Dec;17(6):512-7
22052379
Future Virol. 2011 Mar;6(3):341-355
21695042
J Virol. 2000 Dec;74(24):11464-71
11090142
Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):E49-55
25535379
Nature. 1983 Dec 1-7;306(5942):478-80
6316159
J Infect Dis. 1973 Sep;128(3):345-7
4353932
Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18820-4
22065742
Continuum (Minneap Minn). 2015 Dec;21(6 Neuroinfectious Disease):1692-703
26633783
N Engl J Med. 1952 Jan 31;246(5):172-6
14890831
J Gen Virol. 2015 Jul;96(Pt 7):1581-602
25794504
Genes Dev. 2012 Jul 15;26(14):1527-32
22802527
J Virol. 1995 Dec;69(12):8151-4
7494340
Methods Cell Biol. 2016;131:365-87
26794524
PLoS Pathog. 2012 Feb;8(2):e1002540
22383875
N Engl J Med. 1978 May 11;298(19):1068-9
205790